Clark Discusses Agility Clinical Acquisition With ClinicalOMICS

 

In the latest edition of ClinicalOMICS, Precision for Medicine President Chad Clark elaborates on the recent acquisition of rare and orphan CRO Agility Clinical. Outlining the expansion of Precision’s oncology and rare disease research expertise, Clark also discusses the advantages of deploying Precision’s rapidly growing EU footprint to better serve Agility’s lab, biomarker, and clinical development needs.

To read the complete article, please click here.